Literature DB >> 21913982

Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation.

Tsung-Ming Chen1, Chun-Che Lin, Pi-Teh Huang, Chen-Fan Wen.   

Abstract

BACKGROUND AND AIM: Increasing evidence correlates the presence of systemic inflammation with poor survival in patients with hepatocellular carcinoma (HCC). We studied whether peripheral blood neutrophil-to-lymphocyte ratio (NLR), a marker of systemic inflammatory response, would be a useful predictor for outcome in patients with early HCC undergoing radiofrequency ablation (RFA).
METHODS: A total of 158 patients with early HCC underwent RFA. Potential prognostic factors such as age, gender, tumoral characteristics, Child-Turcotte-Pugh (CTP) class and NLR were analyzed. The study endpoints were overall survival (OS) and new recurrence.
RESULTS: We modeled NLR as a continuous explanatory variable in regression analyses. Multivariate analysis revealed that tumor size (P = 0.005) and high baseline NLR (P = 0.001) were independent explanatory variables associated with unfavorable OS. Regarding new recurrence, multivariate analysis showed that CTP class B (P = 0.002), α-fetoprotein > 400 ng/mL (P = 0.030), tumor size (P = 0.002) and tumor multiplicity (P = 0.013) were found to be worse prognosticators, but not baseline NLR. In a subset analysis of 140 patients whose post-RFA NLR data at first follow-up visit were available, multivariate analysis revealed that high post-RFA NLR was identified as an independent covariate, not only for OS (P = 0.006), but for new recurrence (P = 0.010) as well.
CONCLUSIONS: High baseline NLR was associated with worse OS for patients with early HCC; post-RFA NLR predicted not only OS, but also tumor recurrence.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21913982     DOI: 10.1111/j.1440-1746.2011.06910.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  67 in total

1.  Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation.

Authors:  Ming-An Yu; Ping Liang; Xiao-Ling Yu; Zhi-Yu Han; Xue-Juan Dong; Y U Wang; Chao Cheng; Xin Li
Journal:  Exp Ther Med       Date:  2015-08-14       Impact factor: 2.447

2.  Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy.

Authors:  Shun-Jun Fu; Shun-Li Shen; Shao-Qiang Li; Yun-Peng Hua; Wen-Jie Hu; Li-Jian Liang; Bao-Gang Peng
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

3.  Neutrophil-lymphocyte ratio as a new predictive and prognostic factor at the hearing loss of diabetic patients.

Authors:  Sahin Ulu; Abdulkadir Bucak; M Sena Ulu; Ahmet Ahsen; Abidin Duran; Fatih Yucedag; Abdullah Aycicek
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10       Impact factor: 2.503

Review 4.  Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis.

Authors:  Matteo Cescon; Valentina Rosa Bertuzzo; Giorgio Ercolani; Matteo Ravaioli; Federica Odaldi; Antonio Daniele Pinna
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

5.  Neutrophil to lymphocyte ratio independently predicts cardiovascular events in patients with chronic kidney disease.

Authors:  Yalcin Solak; Mahmut Ilker Yilmaz; Alper Sonmez; Mutlu Saglam; Erdinc Cakir; Hilmi Umut Unal; Mahmut Gok; Kayser Caglar; Yusuf Oguz; Mujdat Yenicesu; Murat Karaman; Seyit Ahmet Ay; Abduzhappar Gaipov; Suleyman Turk; Abdulgaffar Vural; Juan J Carrero
Journal:  Clin Exp Nephrol       Date:  2012-11-20       Impact factor: 2.801

6.  Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.

Authors:  Kai Wei; Meng Wang; Wei Zhang; Han Mu; Tian-Qiang Song
Journal:  Med Oncol       Date:  2014-05-04       Impact factor: 3.064

7.  Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.

Authors:  Wei Zhang; Gang Zhao; Kai Wei; Qingxiang Zhang; Weiwei Ma; Qiang Wu; Ti Zhang; Dalu Kong; Qiang Li; Tianqiang Song
Journal:  Med Oncol       Date:  2015-03-07       Impact factor: 3.064

8.  Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis.

Authors:  Hajime Aino; Shuji Sumie; Takashi Niizeki; Ryoko Kuromatsu; Nobuyoshi Tajiri; Masahito Nakano; Manabu Satani; Shingo Yamada; Shusuke Okamura; Shigeo Shimose; Hiroaki Sumie; Takuji Torimura; Michio Sata
Journal:  Mol Clin Oncol       Date:  2014-02-14

9.  Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis.

Authors:  Keisuke Arai; Takumi Fukumoto; Masahiro Kido; Motofumi Tanaka; Kaori Kuramitsu; Hisoka Kinoshita; Shohei Komatsu; Daisuke Tsugawa; Sachio Terai; Taku Matsumoto; Tadahiro Goto; Sadaki Asari; Hirochika Toyama; Tetsuo Ajiki; Yonson Ku
Journal:  Surg Today       Date:  2016-07-27       Impact factor: 2.549

10.  Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study.

Authors:  Jiang Long; Jia-sheng Zheng; Bin Sun; Ningning Lu
Journal:  Hepatol Int       Date:  2016-01-07       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.